The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | The three main objectives in multiple myeloma research
In this video, M. Bakri Hammami, MD, Moffitt Cancer Center, Tampa, FL, briefly discusses the three main objectives in multiple myeloma (MM) research: developing novel treatments, risk stratification of patients, and sequencing of therapies. Dr Hammami notes that his research aims to inform treatment decisions in the newly diagnosed setting. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So a key highlight that we noticed in ASCO 2026 and in recent conferences is that there is a focus on three main objectives in all the research that is presented. The first objective is actually and it has always been the development of new therapies and you know showing new therapies that we are using in myeloma and that has been lucrative and very fruitful in the last 15 years actually compared to other oncology fields...
So a key highlight that we noticed in ASCO 2026 and in recent conferences is that there is a focus on three main objectives in all the research that is presented. The first objective is actually and it has always been the development of new therapies and you know showing new therapies that we are using in myeloma and that has been lucrative and very fruitful in the last 15 years actually compared to other oncology fields. And we see many of those research that has been discussed here in ASCO. But the second objective, which I think is equally important, is the risk stratification of the patients. Which patient do we give which treatment? And that’s also important. And the third and I think also equally important objective that is being discussed in these conferences is the sequencing of therapies. Which therapy to use first, on which patient, at what time. And that has been pretty hard to do in the past years because we had a flourish of different treatment options that we’re giving for patients. But I think in our particular research, we are tackling the first part of it, which is the newly diagnosed multiple myeloma. And we’re starting there because that’s where a lot of the physicians in the community and in the field are starting. And we’re showing that, yes, we do have a lot of options. Some options are better in terms of safety. Some options are better in terms of efficacy. At the end of the day, it’s all covered. It’s all based on the patient’s preference and the treatment goals and the guidelines.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
